The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Tags · Access

personal import

Rules on importing for personal use, which vary enormously.

52 topics 13 solved Group: Access

Related in this group: insurance · prior authorisation · appeals · formulary · cost per milligram · compounding · shortage · NHS · EMA · FDA · MHRA · telehealth

52 topics · page 2 of 2

TopicParticipantsRepliesViewsActivity
Revisiting: German, French and Dutch differences, compared
Posting this under the heading it deserves: Revisiting: German, French and Dutch differences, compared Everything below is what sits behind that. A coverage question with the paperwork detail included, since…
ITKSTHEDS+90 99 32k 9mo
About the European Union category
EMA positions, national differences within the EU, and cross-border purchase rules. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…
SLTVGRPTC+1 5 18k 10mo
EU-wide position versus national implementation
EU-wide position versus national implementation Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because everything in this category…
BBCLSGLEVK+22 29 356 11mo
Cross-border purchase within the EU: the actual rules
Cross-border purchase within the EU: the actual rules Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is…
SCMIBVET+6 10 41k 11mo
Second pass at: Import rules for personal quantities, by jurisdiction, dated
Second pass at: Import rules for personal quantities, by jurisdiction, dated Writing it up because I had to work it out twice and would rather nobody else did. A logistics question, since the answers here are…
DHKAV 2 5k 11mo
Coming back to: Cross-border purchase rules within the EU
Cross-border purchase rules within the EU Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is what…
JEDBNRPFFE+12 16 2.8k 11mo
Revisiting: Why a compound being unapproved is not the same as being illegal to possess
On the subject in the title: Revisiting: Why a compound being unapproved is not the same as being illegal to possess Working notes rather than a conclusion. Structured report rather than an opinion, following…
CHDVRARZMD+76 82 52k 11mo
Import rules for personal quantities, by jurisdiction, dated
On the subject in the title: Import rules for personal quantities, by jurisdiction, dated Working notes rather than a conclusion. Structured report rather than an opinion, following the format the maintainers…
MDFNBRAN 3 60k 12mo
Second pass at: Pharmacy supply in the UK and the questions you will be asked
Second pass at: Pharmacy supply in the UK and the questions you will be asked Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail…
DBDATFHKD+46 53 14k 12mo
Reading a regulatory notice rather than an article about it — what changed since
Reading a regulatory notice rather than an article about it — what changed since — setting out what I have, and where I think it stops being reliable. A logistics question, since the answers here are usually…
NSJRIBTYCC+28 32 640 13mo
UK access routes, dated and sourced — a second dataset
Posting this under the heading it deserves: UK access routes, dated and sourced — a second dataset Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this…
EMGBSTYEM+76 82 25k 14mo
Enforcement priorities versus written rules
Enforcement priorities versus written rules — setting out what I have, and where I think it stops being reliable. I would like to talk about documentation quality as a signal, separately from product quality.…
NSMINV 2 62k 15mo
UK access routes, dated and sourced
UK access routes, dated and sourced Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because everything in this category expires. As of…
NROJC 2 5.8k 15mo
Second pass at: Cross-border purchase within the EU: the actual rules
Posting this under the heading it deserves: Second pass at: Cross-border purchase within the EU: the actual rules Everything below is what sits behind that. Documenting an access outcome, dated, because…
KVMSZILOWM+135 139 8.7k 16mo
How compounding permissions changed when supply normalised
Asking directly, because I could not find a straight answer: How compounding permissions changed when supply normalised Structured report rather than an opinion, following the format the maintainers asked…
GCCCCCMEMP+30 34 51k 16mo
What changed in 2026, by region
What changed in 2026, by region — that is the question, and I have not found it answered plainly anywhere I have looked. Documenting an access outcome, dated, because everything in this category expires. As…
AFNDCNNNID+110 122 1.4k 18mo
[2026 update] EU-wide position versus national implementation
On the subject in the title: EU-wide position versus national implementation Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As of…
FIANDT 2 54k 19mo
Coming back to: Research-use-only labelling: what it means and what it does not
Research-use-only labelling: what it means and what it does not — setting out what I have, and where I think it stops being reliable. Structured report rather than an opinion, following the format the…
RDCCAAPSDO+45 50 39k 20mo
EMA product information as a primary source — does this still hold?
The question in the title: EMA product information as a primary source — does this still hold? I will give what I have already checked below so nobody repeats it. Documenting an access outcome, dated, because…
CCSGRWIAII+127 150 41k 20mo
Second pass at: Reimbursement variation across member states
On the subject in the title: Second pass at: Reimbursement variation across member states Working notes rather than a conclusion. A coverage question with the paperwork detail included, since that is what…
APCDACBRSB+23 28 45k 21mo
About the International category
Country-by-country availability and legality, dated because it changes constantly. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…
TVDOPMAN+6 11 240 22mo
MHRA statements, read directly — the long version
On the subject in the title: MHRA statements, read directly — the long version Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As of…
BRTDSL 2 44k 22mo